Medreich Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Medreich Limited Pharmaceutical Export Portfolio Dataset — 42 Products, $224.8M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Medreich Limited — Pharmaceutical Exporter Profile (2026) | 42 Products, $224.8M Trade | TransData Nexus

Medreich Limited

Indian Pharmaceutical Exporter · Antibiotics Specialist · $224.8M Total Trade · DGFT Verified

Medreich Limited is an Indian pharmaceutical exporter with a total trade value of $224.8M across 42 products in 15 therapeutic categories. Based on 7,285 verified export shipments from Indian Customs (DGFT) records, Medreich Limited is the #1 Indian exporter in 2 products including Flucloxacillin, Benzylpenicillin. Top exports include Amoxicillin ($47.7M), Potassium ($20.9M), Flucloxacillin ($16.9M).

Medreich Limited — Export Portfolio & Destination Treemap

Medreich Limited pharmaceutical export portfolio — 42 products across 15 therapeutic categories. Source: Indian Customs (DGFT).

Who is Medreich Limited? — Company Overview & Market Position

Medreich Limited, established on August 16, 1973, in Bengaluru, Karnataka, India, is a fully integrated pharmaceutical company specializing in contract manufacturing and development of pharmaceutical preparations across various dosage forms. The company operates under the Corporate Identification Number (CIN) U24232KA1973PLC002383. Medreich's authorized capital stands at ₹160.50 crore, with a paid-up capital of ₹40.16 crore.

In 2015, Medreich became a subsidiary of the Meiji Group, a leading Japanese conglomerate listed on the Tokyo Stock Exchange, with business interests spanning pharmaceuticals, food, and nutrition products. The company employs approximately 3,000 individuals worldwide, providing a robust platform for employee growth and development.

What Does Medreich Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Amoxicillin$47.7M 2Potassium$20.9M

Product Portfolio — Top 30 by Export Value

Medreich Limited exports 42 pharmaceutical products across 15 therapeutic categories. Market leader (#1 exporter) in 2 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Amoxicillin	Antibiotics	$47.7M	1,356	7.8%	4
2	Potassium	Nutritional Supplements	$20.9M	704	3.3%	8
3	Flucloxacillin	Advanced Antibiotics	$16.9M	337	43.4%	1
4	Rosuvastatin	Cardiovascular	$16.7M	684	3.6%	8
5	Atorvastatin	Cardiovascular	$14.6M	291	1.3%	10
6	Ezetimibe	Lipid & Metabolism	$12.4M	406	2.4%	5
7	Ibuprofen	Analgesics & Antipyretics	$9.9M	469	1.7%	8
8	Tramadol	Analgesics & Antipyretics	$8.2M	229	2.1%	6
9	Paracetamol	Analgesics & Antipyretics	$8.1M	241	2.3%	7
10	Codeine	Analgesics & Antipyretics	$7.3M	145	6.6%	3
11	Metformin	Diabetes & Endocrine	$6.7M	133	1.4%	11
12	Fexofenadine	Antihistamines & Allergy	$5.7M	163	5.2%	7
13	Amlodipine	Cardiovascular	$5.7M	113	0.0%	10
14	Ampicillin	Antibiotics	$4.1M	102	2.9%	7
15	Bisoprolol	Cardiovascular	$4.0M	265	4.8%	5
16	Caffeine	Respiratory & OTC	$4.0M	133	3.7%	5
17	Gliclazide	Advanced Diabetes Medications	$3.6M	82	1.2%	8
18	Sertraline	CNS & Psychiatric	$2.4M	70	0.4%	12
19	Loratadine	Antihistamines & Allergy	$2.3M	203	1.3%	10
20	Fluoxetine	CNS & Psychiatric	$2.2M	126	0.9%	11
21	Erythromycin	Antibiotics	$2.1M	96	2.7%	5
22	Glimepiride	Diabetes & Endocrine	$2.1M	42	2.8%	5
23	Pravastatin	Cardiovascular	$2.0M	41	6.6%	4
24	Benzylpenicillin	Advanced Antibiotics	$1.9M	46	50.4%	1
25	Naproxen	Analgesics & Antipyretics	$1.9M	101	1.4%	14
26	Glucosamine	Nutritional Supplements	$1.4M	27	10.2%	3
27	Aspirin	Analgesics & Antipyretics	$1.2M	141	3.2%	12
28	Famotidine	Gastrointestinal	$1.1M	23	2.1%	6
29	Loperamide	Gastrointestinal	$1.1M	112	1.5%	10
30	Salicylic	Combination Drugs	$1.0M	77	6.0%	5

Medreich Limited exports 42 pharmaceutical products across 15 therapeutic categories with a total export value of $224.8M. The company is the #1 Indian exporter in 2 products: Flucloxacillin, Benzylpenicillin. The top category is Antibiotics (24.1% of portfolio), followed by Cardiovascular (19.7%), reflecting a diversified portfolio where the top 5 products account for only 51.9% of total value.

Showing top 30 of 42 products. Contact us for complete data.

Medreich Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Medreich operates multiple state-of-the-art manufacturing facilities in India, including six in Bengaluru and one in Hyderabad. These facilities are approved by various regulatory authorities, including the UK's MHRA, Australia's TGA, Health Canada, Japan's PMDA, South Korea's MFDS, and South Africa's MCC. The manufacturing units are equipped to produce a range of dosage forms, such as tablets, capsules, dry powders for suspensions, and dry powder for injections, adhering to stringent GMP standards.

3Key Leadership

As of July 31, 2023, Tsutomu Yamada serves as a Director at Medreich Limited. Pankaj Garg has been the Managing Director since July 31, 2015. Yasuhiro Nakagiri joined as an Additional Director on May 9, 2024. The leadership team is committed to driving the company's vision of global expansion through strong local partnerships.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Medreich Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Medreich has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained approvals from regulatory bodies such as the UK's MHRA, Australia's TGA, Health Canada, Japan's PMDA, South Korea's MFDS, and South Africa's MCC. These approvals enable Medreich to supply pharmaceutical products to over 55 countries, including key markets in Europe, Australia, New Zealand, Canada, Japan, Far East Asia, GCC, Africa, Latin America, and the CIS.

2Emerging Markets

Medreich has expanded its footprint in emerging markets across Africa, Latin America, and Southeast Asia. The company's manufacturing facilities are approved by regulatory authorities in these regions, including South Africa's MCC and various Latin American countries. Additionally, Medreich has established subsidiaries in the United Kingdom and Australia, further enhancing its presence in these emerging markets.

3Geographic Strategy

Medreich's geographic strategy focuses on diversification across multiple regions, including Europe, Australia, New Zealand, Canada, Japan, Far East Asia, GCC, Africa, Latin America, and the CIS. This approach mitigates concentration risk and aligns with the company's vision of global expansion through strong local partnerships. The strategic direction emphasizes the development of patent non-infringing and niche generics in differentiated dosage forms for global regulated markets.

Medreich Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Medreich's manufacturing facilities are approved by the US FDA, enabling the company to supply pharmaceutical products to the United States market. The company has a track record of obtaining market authorizations in various regions, including the US, UK, Europe, Australia, New Zealand, Canada, Far East Asia, Latin America, and Africa. This regulatory compliance underscores Medreich's commitment to maintaining high-quality manufacturing standards.

2WHO & EU GMP

Medreich's manufacturing facilities comply with WHO-GMP standards, ensuring the production of high-quality pharmaceutical products. The company's facilities are also approved by the UK's MHRA, Australia's TGA, Health Canada, Japan's PMDA, South Korea's MFDS, and South Africa's MCC, reflecting adherence to international GMP standards. These certifications facilitate access to global markets and reinforce Medreich's commitment to quality.

3CDSCO & Indian Regulatory

Medreich holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) in India, ensuring compliance with national regulatory standards. The company's facilities are approved by various state drug controllers, and it possesses export No Objection Certificates (NOCs) for international shipments. These regulatory approvals demonstrate Medreich's adherence to both domestic and international standards.

Medreich Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Medreich operates in a competitive landscape with several key players in the pharmaceutical manufacturing sector. The company's product portfolio includes antibiotics, cardiovascular drugs, and analgesics, with top products such as Flucloxacillin, Amoxicillin, and Rosuvastatin. Medreich's manufacturing facilities are approved by various regulatory authorities, including the UK's MHRA, Australia's TGA, Health Canada, Japan's PMDA, South Korea's MFDS, and South Africa's MCC, enabling the company to supply products to over 55 countries. This extensive regulatory compliance and global reach position Medreich as a significant player in the pharmaceutical manufacturing industry.

2Key Differentiators

Medreich's key differentiators include its fully integrated operations, advanced research and development capabilities, and a strong focus on regulatory compliance. The company's manufacturing facilities are approved by various regulatory authorities, including the UK's MHRA, Australia's TGA, Health Canada, Japan's PMDA, South Korea's MFDS, and South Africa's MCC, ensuring adherence to international standards. Additionally, Medreich's strategic partnerships with multinational companies and its presence in over 55 countries underscore its competitive advantages in the pharmaceutical manufacturing sector.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Medreich Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Medreich has a strong track record in pharmaceutical manufacturing, with a total export value of $224.8 million USD and 7,285 shipments across 42 products in 15 therapeutic categories. The company's top five products—Flucloxacillin, Amoxicillin, Potassium, Rosuvastatin, and Atorvastatin—account for 51.9% of its portfolio, indicating a focused product strategy. Medreich's manufacturing facilities are approved by various regulatory authorities, including the UK's MHRA, Australia's TGA, Health Canada, Japan's PMDA, South Korea's MFDS, and South Africa's MCC, ensuring compliance with international standards. These factors contribute to Medreich's reliability as a supplier in the pharmaceutical industry.

2Certifications to Verify

Importers should verify the following certifications when sourcing from Medreich Limited:

FDA Approval: Confirm that Medreich's manufacturing facilities are registered with the US FDA. This can be verified through the FDA's Establishment Registration & Device Listing database.

WHO-GMP Certification: Ensure that Medreich's facilities comply with WHO-GMP standards. Verification can be done by reviewing the WHO's list of prequalified manufacturers.

Frequently Asked Questions — Medreich Limited

How many pharmaceutical products does Medreich Limited export from India?

Medreich Limited exports 42 pharmaceutical products across 15 therapeutic categories. The top exports are Amoxicillin ($47.7M), Potassium ($20.9M), Flucloxacillin ($16.9M), Rosuvastatin ($16.7M), Atorvastatin ($14.6M). Total export value is $224.8M.

What is Medreich Limited's total pharmaceutical export value?

Medreich Limited's total pharmaceutical export value is $224.8M, based on 7,285 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Medreich Limited the #1 Indian exporter?

Medreich Limited is the #1 Indian exporter in 2 products: Flucloxacillin (43.4% market share), Benzylpenicillin (50.4% market share).

What therapeutic categories does Medreich Limited cover?

Medreich Limited exports across 15 therapeutic categories. The largest are Antibiotics (24.1%, 4 products), Cardiovascular (19.7%, 8 products), Analgesics & Antipyretics (16.3%, 6 products).

Get Full Medreich Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.